Clinical Trials in Phoenix

Showing 13821-13840 of 14,291 trials

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

NCT00637338

PF-04603629 is being investigated for the treatment of Type 2 diabetes mellitus (T2DM). Specifically, PF-04603629 is a protein that is a combination of exendin-4 (a glucagon-like peptide-1 (GLP-1) mimetic currently marketed as Byetta®) fused to human transferrin (a naturally occuring protein) in order to increase the concentration of exendin-4 in the blood. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04603629 following multiple escalating subcutaneous doses in adult subjects with T2DM.

Diabetes Mellitus, Type 2

Pfizer42 participantsStarted Apr 2008

Phoenix, Arizona, United States • Miami, Florida, United States • Wichita, Kansas, United States +1 more locations

COMPLETEDPhase 1< 1 mile

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

NCT00638313

PF 04603629 is a long acting exendin proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and glucose lowering capabilities following a single subcutaneous dose.

Diabetes Mellitus, Type 2

Pfizer71 participantsStarted Aug 2007

Phoenix, Arizona, United States • San Antonio, Texas, United States

COMPLETEDPhase 2< 1 mile

A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension

NCT00325962

The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.

Hypertension

BioMarin Pharmaceutical84 participantsStarted May 2006

Hoover, Alabama, United States • Huntsville, Alabama, United States • Mobile, Alabama, United States +21 more locations

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension

Find Trials by Condition in Phoenix

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Duloxetine Versus Placebo for Osteoarthritis Knee Pain

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

Study Evaluating rFIX; BeneFIX® in Hemophilia B

ARQ 197 in Subjects With Metastatic Solid Tumors

Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in Women

Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients